Table 2. Presence of FLT3-ITD and mutated NPM1 in ALDHbright and ALDHlow compartments in CD34-positive AML.
Patient # FLT3-ITD | CD34– cells | CD34+CD38 ALDHlow | CD34+CD38– ALDHbright |
575 | pos | 50% ITD | wt |
808 | pos | 50% ITD | wt |
951 | pos | 42% ITD | wt |
966 | pos | 43% ITD | wt |
1263 | pos | 60% ITD | wt |
Patient # NPM1 | CD34– cells | CD34+CD38 ALDHlow | CD34+CD38 ALDHbright |
575 | mut | mut | wt |
808 | mut | mut | wt |
945 | mut | mut | wt (<5%) |
670 | mut | mut | wt |
Detection of molecular aberrancies in CD34+CD38– ALDHbright and ALDHlow compartments of CD34-positive AML. The FLT3-ITD percentage is determined in the total leukemic blast population (data not shown), the CD34– cell population and the CD34+CD38-ALDHlow and CD34+CD38-ALDHbright compartments. The NPM1 mutation analysis is not quantative. # the ALDHbright compartment contained in one case a small mutant peak (AML-945), likely caused by relatively poor separation of ALDHbright and ALDHlow populations due to overlap in the boundary region.